OncoSec jumps into TNBC CAR T therapy via Dana-Farber deal

By partnering with a Dana-Farber antibody engineering expert and leveraging the institute’s cell manufacturing capabilities, cytokine therapeutics company OncoSec is expanding into CAR T cell therapies for solid tumors. The deal highlights how manufacturing-savvy academic centers provide a cost-effective way for companies to explore new modalities that could synergize with their existing pipelines.